A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent strengthens CVC's leading position in ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

Suffering on such an immense scale can appear hopeless. However, a technique called CRISPR gene editing promises to help deal with these issues and many more—and wise regulation can spur it on.

24, 2025 (GLOBE NEWSWIRE) -- SNIPR BIOME ApS (“SNIPR” or “the Company”), a clinical stage biotech company pioneering CRISPR-based therapies, today announces grant of patent EP4392563B on ...

Currently, these technologies are subject to the EU’s strict GMO regulation, making their commercialisation in the bloc ...

European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent strengthens CVC's leading position in European ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...